Pharmacological targeting of the FGFR-KLB system dramatically improves metabolic disturbances in rodent models of obesity, T2D, and NAFLD, observations that paved the way for more advanced drug development. Here, KLB is linked to obesity due to melanocortin 4 receptor deficiency.